PerpEquities

SELLAS Life Sciences Group, Inc. (SLS) cash flow statement

NASDAQ · Healthcare · Biotechnology · 13 employees · CEO Angelos Stergiou

Price
$14.69 +2.0%
Market cap
$2.78B
Enterprise value
$2.65B Data as of 2026-11-21
Last report
Q3 '26 filed 2026-11-12
Next report
2027-03-25 EPS est. -$0.05

In Q3 '26 SELLAS Life Sciences Group, Inc. (SLS) generated -$5.94M of operating cash flow, invested $0 in capital expenditure and kept -$5.94M of free cash flow. Over the last four quarters free cash flow was -$27.3M.

Cash flow

Cash flowTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Operating
Net income-$8.14M-$9.57M-$7.47M-$7.11M-$6.74M-$5.81M-$6.6M-$6.79M-$7.66M-$8.41M-$9.61M-$10.1M
Depreciation & amortization$0$0$0$0$0$0$0$7.08M$0$0$0$152K
Stock-based compensation$497K$476K$334K$381K$373K$505K$501K$503K$447K$798K$1.02M$1.93M
Change in working capital$2.69M-$1.81M-$1.63M-$1.22M-$937K-$3.91M-$1.38M-$927K$2.14M-$1.39M$848K$2.07M
Other non-cash items$128K$138K-$921K$137K$148K$147K$149K-$6.94M$154K$153K$154K$0
Operating cash flow-$4.83M-$10.8M-$9.68M-$7.81M-$7.15M-$9.07M-$7.33M-$7.07M-$4.92M-$8.85M-$7.59M-$5.94M
Investing
Capital expenditure-$5.5M$0$0$0$0$0$0$0$0$0$0$0
Other investing$5.5M$0$0$0$0$0$0$0$0$0$0$0
Financing
Other financing (incl. tax on vested shares)-$17K$100K$355K$202K-$63K$0$0$0-$527K$0$66K$0
Financing cash flow$3.39M$26.6M$414K$19.7M$8K$23.6M$4.23M$26.1M$32.4M$44.2M$38.8M$2.31M
Summary
Net change in cash-$1.44M$15.9M-$9.27M$11.9M-$7.15M$14.5M-$3.1M$19M$27.5M$35.3M$31.2M-$3.63M
Free cash flow (OCF - capex)-$10.3M-$10.8M-$9.68M-$7.81M-$7.15M-$9.07M-$7.33M-$7.07M-$4.92M-$8.85M-$7.59M-$5.94M
Interest paid$0$0$0$0$0$0$0$0$0$0$1.02M$0

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-21